Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 2a, Open-label, Non-randomized Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

NCT04669600 is registered in ClinicalTrials.gov with Bioverativ, a Sanofi company as lead sponsor.

NCT NCT04669600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04669600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 2a, Open-label, Non-randomized Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)
Lead sponsor
Bioverativ, a Sanofi company
Phase
Phase 2
Overall status
Completed
Start date
February 4, 2021
Completion date
February 7, 2023
Enrollment
12 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia (itp)